| 徐宜全,姚型锋,卢其香.局限期小细胞肺癌放化疗的疗效及预后因素[J].肿瘤学杂志,2018,24(5):434-438. |
| 局限期小细胞肺癌放化疗的疗效及预后因素 |
| Curative Effect and Prognosis Factors for Patients with Limited-stage Small Cell Lung Cancer Treated with Chemoradiotherapy |
| 投稿时间：2017-04-24 |
| DOI：10.11735/j.issn.1671-170X.2018.05.B005 |
|
 |
| 中文关键词: 小细胞肺癌 局限期 放射疗法 化学疗法 疗效 预后因素 |
| 英文关键词:small cell lung cancer limited stage chemoradiotherapy curative effect prognostic factor |
| 基金项目: |
|
| 摘要点击次数: 1916 |
| 全文下载次数: 491 |
| 中文摘要: |
| 摘 要：［目的］ 探讨局限期小细胞肺癌（LS-SCLC）放化疗的疗效及其预后影响因素。［方法］ 回顾性收集2010年1月至2015年6月我院收治的接受放化疗的LS-SCLC患者142例，观察患者近期疗效及不良反应，Kaplan-Meirer法绘制生存曲线和肿瘤无进展生存曲线，对影响患者预后的相关因素行Log-Rank单因素分析和Cox多因素分析。［结果］ 全组142例LS-SCLC患者经过放化疗后，54例（38.0%）完全缓解、66例（46.5%）部分缓解、16例（11.3%）病变稳定、6例（4.2%）病变进展。患者主要的不良反应有骨髓抑制（114/142，80.3%）、胃肠道反应（107/142，75.4%）、放射性食管炎（71/142，50.0%）和放射性肺炎（28/142，19.7%）。随访3～80个月，患者1、3、5年的总生存率为87.2%、33.6%和22.3%，中位生存时间为24个月；患者1、3、5年的肿瘤无进展生存率为54.5%、26.9%和12.2%，肿瘤无进展中位生存时间为14个月。 多因素分析表明KPS评分＜80分、非同步放化疗为LS-SCLC患者放化疗预后的独立危险因素（P＜0.05）。［结论］ LS-SCLC患者放化疗取得较好的疗效，同步放化疗预后优于非同步放化疗，KPS评分＜80分是LS-SCLC的独立危险因素。 |
| 英文摘要: |
| Abstract：［Objective］ To assess the curative effect and prognosis factors for patients with limited-stage small cell lung cancer(LS-SCLC) treated with chemoradiotherapy. ［Methods］ Total 142 patients with LS-SCLC treated with chemoradiotherapy in our institution from Jan 2010 to Jun 2015 were reviewed retrospectively. Short-term curative effect and adverse reactions were observed. The Kaplan-Meirer method was used to evaluate the overall survival(OS) and progression-free survival(PFS). Clinical factors that may affect prognosis were analyzed by Log-Rank test and Cox regression model. ［Results］ After chemoradiotherapy，complete remission(CP) was in 54(38.0%) cases，partial remission(PR) in 66(46.5%) cases，stable disease(SD) in 16(11.3%) cases，and disease progress(DP) in 6(4.2%) cases. The main adverse reactions were myelosuppression(114/142，80.3%)，gastrointestinal reaction(107/142，75.4%)，radiation esophagitis(71/142，50.0%) and radiation pneumonitis(28/142，19.7%). During the 3～80 months follow-up period，the 1-，3-，and 5-years OS rate was 87.2%，33.6%，and 22.3%，respectively，and the median survival time was 24 months. The 1-，3-，and 5-years PFS rate was 54.5%，26.9%，and 12.2%，respectively，and the median progression-free survival time was 14 months. Multivariate analysis showed that KPS score＜80 and asynchrony chemoradiotherapy were independent risk factors for prognosis in patients with LS-SCLC treated with chemoradiother；and the outcome of concurrent radiochemotherapy was better than that of asynchrony chemoradiotherapy. KPS score＜80 was an independent risk factor for poor prognosis in patients with LS-SCLC.［Conclusion］ Curative effect of chemoradiotherapy in patients with LS-SCLC is good. And compare with asynchrony chemoradiotherapy，outcome of concurrent radiochemotherapy is better. The KPS score ＜80 is an independent risk factor for prognosis in patients with LS-SCLC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |